Risk of testicular germ cell cancer in relation to variation in maternal and offspring cytochrome P450 genes involved in catechol estrogen metabolism

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 9, 2005, Pages 2183-2190

  Starr, Jacqueline R ^a,b,c   Chen, Chu ^b,d   Doody, David R ^d   Hsu, Li ^b,d   Ricks, Sherianne ^d   Weiss, Noel S ^b,d   Schwartz, Stephen M ^b,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL ESTROGEN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; ESTROGEN METABOLISM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERM CELL TUMOR; HETEROZYGOTE; HOMOZYGOSITY; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGENY;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ESTROGENS, CATECHOL; FEMALE; GENOTYPE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PEDIGREE; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 27744520949     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0749     Document Type: Article

References (64)

1. Schottenfeld D. Testicular cancer. In: Schottenfeld D, Fraumeni JF, Jr., editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. p. 1207-19.
2. Strohsnitter WC, Noller KL, Hoover RN, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst 2001;93:545-51.
3. Nef S, Shipman T, Parada LF. A molecular basis for estrogen-induced cryptorchidism. Dev Biol 2000;224:354-61.
4. McLachlan JA, Newbold RR, Li S, Negishi M. Are estrogens carcinogenic during development of the testes? APMIS 1998;106:240-2.
5. Coupland CA, Forman D, Chilvers CE, Davey G, Pike MC, Oliver RT. Maternal risk factors for testicular cancer: a population-based case-control study (UK). Cancer Causes Control 2004;15:277-83.
6. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000;21:361-70.
7. Kuchino Y, Mori F, Kasai H, et al. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature 1987;327:77-9.
8. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;75-93.
9. Aitken RJ, Gordon E, Harkiss D, et al. Relative impact of oxidative stress on the functional competence and genomic integrity of human spermatozoa. Biol Reprod 1998;59:1037-46.
10. Alvarez JG, Touchstone JC, Blasco L, Storey BT. Spontaneous lipid peroxidation and production of hydrogen peroxide and superoxide in human spermatozoa. Superoxide dismutase as major enzyme protectant against oxygen toxicity. J Androl 1987;8:338-48.
11. Fraga CG, Motchnik PA, Wyrobek AJ, Rempel DM, Ames BN. Smoking and low antioxidant levels increase oxidative damage to sperm DNA. Mutat Res 1996;351:199-203.
12. Peltola V, Mantyla E, Huhtaniemi I, Ahotupa M. Lipid peroxidation and antioxidant enzyme activities in the rat testis after cigarette smoke inhalation or administration of polychlorinated biphenyls or polychlorinated naphthalenes. J Androl 1994;15:353-61.
13. Seegers JC, Nieuwoudt LB, Joubert WS. Morphological effects of the catechol estrogens on rat epididymal epithelia. J Steroid Biochem Mol Biol 1991;38:717-20.
14. Seegers JC, van Aswegen CH, Nieuwoudt BL, Joubert WS. Morphological effects of the catecholestrogens on cells of the seminiferous tubules of Sprague-Dawley rats. Andrologia 1991;23:339-45.
15. Metzler M. Metabolic activation of xenobiotic stilbene estrogens. Fed Proc 1987;46:1855-7.
16. Weinberg CR, Wilcox AJ, Lie RT. A log-linear approach to case-parent-triad data: assessing effects of disease genes that act either directly or through maternal effects and that may be subject to parental imprinting. Am J Hum Genet 1998;62:969-78.
17. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27.
18. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYPSA-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271-94.
19. Shou M, Korzekwa KR, Brooks EN, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 1997;18:207-14.
20. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, Gonzalez FJ. Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 1990;126:3101-6.
21. Zheng W, Xie DW, Jin F, et al. Genetic polymorphism of cytochrome P 450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:147-50.
22. Allen AS, Rafhouz PJ, Satten GA. Informative missingness in genetic association studies: case-parent designs. Am J Hum Genet 2003;72:671-80.
23. Wilcox A, Weinberg CR, Lie RT. Distinguishing the effects of maternal and offspring genes through studies of case-parent triads. Am J Epidemiol 1998;148:893-901.
24. Weinberg CR. Allowing for missing parents in genetic studies of case-parents triads. Am J Hum Genet 1999;64:1186-93.
25. van Den Oord EJ, Vermunt JK. Testing for linkage disequilibrium, maternal effects, and imprinting with (in)complete case-parent triads, by use of the computer program LEM. Am J Hum Genet 2000;66:335-8.
26. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002;32:165-206.
27. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004;279:23847-50.
28. Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995;5:259-74.
29. Berg FD, Kuss E. 2-Hydroxylation and O-methylation of oestrogens by human placenta in vivo. Acta Endocrinol (Copenh) 1987;115:272-4.
30. Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, Winn LM. Oxidative damage in chemical teratogenesis. Mutat Res 1997;396:65-78.
31. Hardell L, Van Bavel B, Lindstrom G, et al. Concentrations of polychlorinated biphenyls in blood and the risk for testicular cancer. Int J Androl 2004;27:282-90.
32. Nordmark A, Lundgren S, Ask B, Granath F, Rane A. The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 2002;54:504-10.
33. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
34. Castorena-Torres F, Mendoza-Cantu A, de Leon MB, et al. CYP1A2 phenotype and genotype in a population from the carboniferous region of Coahuila, Mexico. Toxicol Lett 2005;156:331-9.
35. Vistisen K, Loft S, Olsen JH, et al. Low CYP1A2 activity associated with testicular cancer. Carcinogenesis 2004;25:923-9.
36. Lippert TH, Seeger H, Mueck AO. The impact of endogenous estradiol metabolites on carcinogenesis. Steroids 2000;65:357-69.
37. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology 2003;144:3382-98.
38. Bolton JL, Chang M. Quinoids as reactive intermediates in estrogen carcinogenesis. Adv Exp Med Biol 2001;500:497-507.
39. Han XM, Ou-Yang DS, Lu PX, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001;11:429-35.
40. Obase Y, Shimoda T, Kawano T, et al. Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 2003;73:468-74.
41. Aklillu E, Carrillo JA, Makonnen E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003;64:659-69.
42. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209-16.
43. Hefler LA, Tempfer CB, Grimm C, et al. Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 2004;101:264-9.
44. Sachse C, Smith G, Wilkie MJ, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002;23:1839-49.
45. Aitchison KJ, Gonzalez FJ, Quattrochi LC, et al. Identification of novel polymorphisms in the 5′ flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics 2000;10:695-704.
46. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004;43:487-514.
47. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000;10:343-53.
48. McLellan RA, Oscarson M, Hidestrand M, et al. Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys 2000;378:175-81.
49. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
50. 432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000;10:761-6.
51. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999;20:1607-13.
52. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000;60:3440-4.
53. Cook LS, Doherty JA, Weiss NS, Chen C. Endometrial cancer: epidemiology and molecular endocrinology. In: Henderson BE, Ponder B, Ross RK, editors. Hormones, genes, and cancer. New York: Oxford University Press; 2003.
54. Kristensen VN, Borresen-Dale AL. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 2000;462:323-33.
55. Rylander-Rudqvist T, Wedren S, Granath F, et al. Cytochrome P 450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis 2003;24:1533-9.
56. Saintot M, Malaveille C, Hautefeuille A, Gerber M. Interactions, between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk. Int J Cancer 2003;107:652-7.
57. Chang BL, Zheng SL, Isaacs SD, et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003;89:1524-9.
58. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61:586-94.
59. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
60. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-72.
61. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988;263:424-36.
62. Skakkebaek NE. Testicular dysgenesis syndrome: new epidemiological evidence. Int J Androl 2004;27:189-91.
63. Zhang Y, Graubard BI, Klebanoff MA, et al. Maternal hormone levels among populations at high and low risk of testicular germ cell cancer. Br J Cancer 2005;92:1787-93.
64. Starr JR, Hsu L, Schwartz SM. Performance of the log-linear approach to case-parent triad data for assessing maternal genetic associations with offspring disease: type I error, power, and bias. Am J Epidemiol 2005;161:196-204.